ANXA6 (Annexin A6)

Conversely, combining NK cell adoptive transfer therapy with PARPi markedly prolongs survival in mice bearing PCa. Collectively, we reveal a unique secretory crosstalk between PCa cells and NK cells induced by PARPi and propose a promising strategy for treating PCa.

The inhibitory phosphorylation of GSK-3β (p-S9) increased in paclitaxel resistant epithelial cells but decreased in resistant mesenchymal-like TNBC cells...These data reveal that chemotherapy resistance of epithelial and mesenchymal-like TNBC cellular subsets upregulated distinct profiles of proinflammatory and immune cell chemotactic cytokines and modulated the activities of GSK-3β, p90 RSK1/2 and the related MSK1/2. Targeting these factors and/or the associated signaling pathways may help overcome chemotherapy resistance in TNBC.

Overall, TGFBI and ANXA6 are crucial in UCRCC, serving as novel diagnostic markers. They exhibit robust predictive capabilities on patient prognosis and immunotherapy response, offering actionable insights to optimize therapeutic decision-making and advance personalized treatment paradigms in UCRCC management.

By addressing underlying patterning processes and plasticity networks as therapeutic vulnerabilities, our findings provide precision medicine strategies aimed at modulating glioma cell fates and overcoming therapeutic resistance. We suggest transition therapy toward neuronal-like lineage differentiation as a potential precision therapy to help stabilize pHGG plasticity and aggressivity.

By constructing the first malonylation protein modification map in goats and revealing dynamic changes during intramuscular preadipocyte differentiation, this research offers novel insights into the regulatory roles of malonylation in fat deposition. The findings not only advance the field of livestock proteomics but also provide a theoretical foundation for improving meat quality and exploring metabolic regulation in animals.

Bioinformatics analysis identified six exosome-associated osteosarcoma genes (WNT5A, GCA, ANXA6, BIRC5, IL1β, and ARPC3) that could serve as potential biomarkers. Through screening, Mifepristone, which can act on BIRC5 and IL1β at the same time, has a very effective osteosarcoma treatment effect.

Overexpression of ANXA6 weakened the inhibitory effect of UA on the proliferation of 231 cells (P<0.05).The results of immunohistochemistry assay showed that the expression level of ANXA6 in breast cancer tissue was significantly increased, and the expression of ANXA6 was related to tumor size (P<0.05), but not to age, T stage, N stage, pathological grade, AJCC stage, ER, PR and E-cad. The expression level of ANXA6 in breast cancer tissues is increased, and UA can inhibit the growth, invasion and metastasis of 231 cells by down-regulating the expression of ANXA6.

This study provides new insights into the shared molecular mechanisms between AD and nHIBD. These common pathways and hub genes could potentially be used to design therapeutic interventions, reducing the likelihood of Alzheimer's disease development in survivors of neonatal Hypoxic-Ischemia brain injury.

Finally, we found that both conotoxins reduced the tumor mass in MPM xenografts; s-cal14.1b reached statistical significance. Based on these results, s-cal14.1b and s-cal14.2b conotoxins could be potential therapeutic drugs for MPM neoplasms with no apparent side effects on normal cells.

ANXA6, negatively correlated with NPC development and metastasis, is a potential prognostic biomarker with tumor-suppressing effects. Multi-omics analysis highlights its clinical and immune regulatory roles, offering insights for future biomarker and molecular mechanism studies in NPC.

Our study reveals the mechanism by which ANXA6 enhances cisplatin sensitivity and re-sensitizes resistant cells. The roles of PRRX1 and ANXA6 in cisplatin resistance offer new therapeutic targets to overcome cisplatin resistance in clinical practice.